Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Innoviva, Inc.INVA · Entity 4679 | Director | April 20, 2017 | April 24, 2017 |
| LANNETT CO INCLCI · Entity 122287 | Director | November 10, 2022 | November 14, 2022 |
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Director | November 02, 2020 | November 10, 2020 |
| Yarrow Bioscience, Inc.VYNE · Entity 6871 | Director | December 12, 2025 | December 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Innoviva, Inc.
Report date April 20, 2017 · Filed April 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,278 |
Reported balance
After 2017-04-20 transaction · row 1
1 source rowRow 1 · 2017-04-20 · Grant · Acquired 19,857 · Balance 58,278 F1: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual shareholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual shareholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.
LANNETT CO INC
Report date November 10, 2022 · Filed November 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 587,145 |
Reported balance
After 2022-11-10 transaction · row 1
1 source rowRow 1 · 2022-11-10 · Purchase · Acquired 100,000 · Balance 587,145 F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging between $0.47 and $0.52. The reporting person undertakes to provide to Lannett Company, Inc., any security holder of Lannett Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging between $0.47 and $0.52. The reporting person undertakes to provide to Lannett Company, Inc., any security holder of Lannett Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
Matinas BioPharma Holdings, Inc.
Report date November 02, 2020 · Filed November 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2030-11-02 | Direct | 122,605 |
Reported balance
After 2020-11-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-11-02 · Grant · Acquired 122,605 · Balance 122,605 F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.
Yarrow Bioscience, Inc.
Report date December 12, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2035-12-11 | Direct | 20,000 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 20,000 · Balance 20,000 F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PharMerica CORP
Report date December 07, 2017 · Filed December 08, 2017
Section 16 reporting ended · disclosed 2017-12-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-07 transaction · row 1
1 source rowRow 1 · 2017-12-07 · Disposition to issuer · Disposed 29,570 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) each share of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (ii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, multiplied by (y) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) each share of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (ii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, multiplied by (y) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2025 Filed Dec 15, 2025 16:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001055404-25-000004 · form4-12152025_041205.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-12-11 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 18:06 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | PurchaseCommon Stock | 15,000 | $2.92 | $43,800.00 |
DisclosureSEC source: 0001415889-25-001574 · form4-01162025_110115.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,472 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $2.8776 to $2.9836, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 16:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-24-029290 · form4-12132024_041215.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-12-11 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 17:13 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001209191-24-000462 · doc4.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-31 F1 · derivative.exercise_date: The shares subject to the option vest on January 1, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 17:05 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-23-058812 · doc4.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-12 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest on December 13, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 17:03 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | PurchaseCommon Stock | 13,000 | $3.91 | $50,778.00 |
DisclosureSEC source: 0001209191-23-055787 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,472 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $3.57 to $4.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 16:03 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | PurchaseCommon Stock | 20,000 | $2.48 | $49,680.00 |
DisclosureSEC source: 0001209191-23-020480 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,472 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $2.464 to $2.5199, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: On February 10, 2023, the Issuer effected a one-for-18 reverse split of its Common Stock. The number of securities reported reflects the reverse split. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 16:16 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 100,000 | $0.49 | $49,000.00 |
DisclosureSEC source: 0001209191-22-056589 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,145 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging between $0.47 and $0.52. The reporting person undertakes to provide to Lannett Company, Inc., any security holder of Lannett Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 17:11 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 20,500 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001209191-22-045651 · doc4.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2032-08-10 F1 · derivative.exercise_date: Represents the annual award to non-executive directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest over a 12-month period in equal, monthly installments, ending August 10, 2023. Read SEC document |
| May 16, 2022 Filed May 17, 2022 16:16 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 50,000 | $0.54 | $27,000.00 |
DisclosureSEC source: 0001209191-22-029599 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,145 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging between $0.51 and $0.56. The reporting person undertakes to provide to Lannett Company, Inc., any security holder of Lannett Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 17:17 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 50,000 | $0.88 | $44,000.00 |
DisclosureSEC source: 0001209191-22-008540 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,145 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging between $0.87 to $0.90. The reporting person undertakes to provide to Lannett Company, Inc., any security holder of Lannett Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 17:08 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | PurchaseCommon Stock | 12,500 | $1.02 | $12,698.75 |
DisclosureSEC source: 0001209191-21-067647 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 F1 · kind: Shares were purchased pursuant to a 10b5-1 plan entered into by the reporting person on April 21, 2021. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.98 to $1.03, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 16:05 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 50,000 | $1.71 | $85,500.00 |
DisclosureSEC source: 0001209191-21-067118 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,145 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.66 to $1.76. The reporting person undertakes to provide to Lannett Company, Inc., any security holder of Lannett Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:07 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 20,000 | $3.31 | $66,200.00 |
DisclosureSEC source: 0001209191-21-055276 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,145 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.28 to $3.35. The reporting person undertakes to provide to Lannett Company, Inc., any security holder of Lannett Company, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 18:30 UTC | LANNETT CO INC LCI · Entity 122287 | GrantCommon Stock | 56,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054553 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,145 F1 · shares: Represents restricted stock awards that vested in full on August 31, 2021 Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 17:04 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | PurchaseCommon Stock | 12,500 | $1.60 | $20,000.00 |
DisclosureSEC source: 0001209191-21-053498 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.59 to $1.60, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 17:06 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 20,500 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001209191-21-047411 · doc4.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2031-07-19 F1 · derivative.exercise_date: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022. Read SEC document |
| May 26, 2021 Filed May 27, 2021 17:18 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | PurchaseCommon Stock | 12,500 | $3.60 | $44,957.50 |
DisclosureSEC source: 0001209191-21-036302 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.48 to $3.6950, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2021 Filed May 12, 2021 16:50 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 20,000 | $4.18 | $83,600.00 |
DisclosureSEC source: 0001209191-21-032077 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,326 Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 16:38 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | PurchaseCommon Stock | 12,500 | $7.41 | $92,562.50 |
DisclosureSEC source: 0001209191-21-020834 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.39 to $7.42, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 16:31 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | PurchaseCommon Stock | 50,000 | $1.71 | $85,425.00 |
DisclosureSEC source: 0001209191-20-061946 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · kind: Shares purchased pursuant to a 10b5-1 plan. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.69 to $1.735, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2020 Filed Nov 10, 2020 16:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 122,605 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-020925 · ownership.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,605 Underlying: Common Stock · 122,605 shares Expires 2030-11-02 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 16:39 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 45,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001209191-20-050292 · doc4.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-09-10 F1 · derivative.exercise_date: The option will vest and become exercisable as to 1/3rd of the shares subject to the option on each annual anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:25 UTC | LANNETT CO INC LCI · Entity 122287 | GrantCommon Stock | 38,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-049400 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,326 F1 · shares: Represents restricted stock awards that vested in full on September 1, 2020 Read SEC document |
| May 14, 2020 Filed May 18, 2020 10:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 100,000 | $0.73 | $73,050.00 |
DisclosureSEC source: 0001493152-20-009278 · ownership.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.7248 to $0.7399, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth herein. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 10:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 100,000 | $1.06 | $105,530.00 |
DisclosureSEC source: 0001493152-19-017920 · ownership.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 107,416 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001493152-19-016458 · ownership.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,416 Underlying: Common Stock · 107,416 shares Expires 2029-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:15 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 25,000 | $9.82 | $245,500.00 |
DisclosureSEC source: 0001209191-19-048496 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,340 Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 10:02 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 100,000 | $0.72 | $71,850.00 |
DisclosureSEC source: 0000905718-19-000714 · matinas_fm4aug162019.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Read SEC document |
| July 19, 2019 Filed Jul 22, 2019 16:25 UTC | LANNETT CO INC LCI · Entity 122287 | GrantCommon Stock | 33,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-042872 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,340 Read SEC document |
| May 16, 2019 Filed May 20, 2019 18:39 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 100,000 | $0.95 | $95,250.00 |
DisclosureSEC source: 0001493152-19-007948 · ownership.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| May 08, 2019 Filed May 9, 2019 16:21 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 25,000 | $7.32 | $183,000.00 |
DisclosureSEC source: 0001209191-19-028478 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,895 Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 16:30 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 25,000 | $8.93 | $223,250.00 |
DisclosureSEC source: 0001209191-19-009634 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,895 Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 11:14 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 25,000 | $5.10 | $127,500.00 |
DisclosureSEC source: 0001209191-18-062863 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,895 Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 08:15 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 128,299 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000905718-18-000905 · ownership.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,299 Underlying: Common Stock · 128,299 shares Expires 2028-10-31 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2018. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| September 05, 2018 Filed Sep 6, 2018 08:20 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantOption (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000905718-18-000782 · ownership.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-09-05 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on October 5, 2018. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 16:19 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 25,000 | $5.34 | $133,500.00 |
DisclosureSEC source: 0001209191-18-049182 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,895 Read SEC document |
| July 20, 2018 Filed Jul 23, 2018 18:19 UTC | LANNETT CO INC LCI · Entity 122287 | GrantCommon Stock | 16,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-043640 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,895 Read SEC document |
| May 11, 2018 Filed May 14, 2018 16:12 UTC | LANNETT CO INC LCI · Entity 122287 | PurchaseCommon Stock | 25,000 | $15.13 | $378,250.00 |
DisclosureSEC source: 0001209191-18-029819 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,700 Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 17:16 UTC | PharMerica CORP PMC · Entity 171237 | Disposition to issuerCommon Stock, $0.01 par value | 29,570 | $29.25 | $864,922.50 |
DisclosureSEC source: 0001209191-17-064772 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of August 1, 2017 (the "Merger Agreement"), by and among PharMerica Corporation (the "Company"), Phoenix Parent Holdings Inc., a Delaware corporation ("Parent"), and Phoenix Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, at the effective time ("Effective Time") of the merger, Merger Sub will merge with and into the Company, with the Company as the surviving entity and a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, as of the Effective Time (i) each share of the Company's common stock, par value $0.01 per share ("Company Common Stock") owned by the reporting person was converted into the right to receive $29.25 in cash without interest (the "Merger Consideration") and (ii) each outstanding restricted stock unit granted by the Company was converted automatically into a right to receive an amount in cash without interest equal to the product of (x) the number of shares of Company Common Stock subject to such unit, multiplied by (y) the Merger Consideration. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 16:43 UTC | PharMerica CORP PMC · Entity 171237 | GrantCommon Stock, $0.01 par value | 4,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040543 · doc4.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,570 Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 21:06 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 19,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006171 · edgar.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,278 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual shareholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| October 26, 2016 Filed Oct 27, 2016 22:31 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 38,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030971 · edgar.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,421 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.